Pre-eclampsia: Relationship between coagulation, fibrinolysis and inflammation

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 17-21

  Dusse, Luci M ^a,b   Rios, Danyelle R A ^b   Pinheiro, Melina B ^b   Cooper, Alan J ^c,d   Lwaleed, Bashir A ^a,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Coagulation; Fibrinolysis; Inflammation; Microparticles; Pre eclampsia

Indexed keywords

APC PROTEIN; BLOOD CLOTTING FACTOR 7; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE ACTIVATED RECEPTOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

BLOOD CLOTTING; CELL HYPOXIA; CLINICAL DECISION MAKING; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; OXIDATIVE STRESS; PLATELET MICROPARTICLE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SHWARTZMAN PHENOMENON; SYNCYTIOTROPHOBLAST; THROMBOCYTE FUNCTION;

EID: 78650512208     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.030     Document Type: Review

References (92)

1. Schuiling G.A., Koiter T.R., Faas M.M. Why pre-eclampsia?. Hum Reprod 1997, 12:2087-2091.
2. National High Blood-Pressure Education-Program Working Group-Report on high blood-pressure in pregnancy. Am J Obstet Gynecol 1990, 163:1691-1712.
3. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., McLaughlin M.K. Preeclampsia - an endothelial-cell disorder. Am J Obstet Gynecol 1989, 161:1200-1204.
4. Brown M.A. The physiology of preeclampsia. Clin Exp Pharmacol Physiol 1995, 22:781-791.
5. Knight M., Redman C.W.G., Linton E.A., Sargent I.L. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998, 105:632-640.
6. Huppertz B., Kingdom J., Caniggia I., et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003, 24:181-190.
7. Sacks G.P., Studena K., Sargent I.L., Redman C.W.G. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998, 179:80-86.
8. Redman C.W.G., Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999, 180:499-506.
9. Redman C.W.G., Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta 2003, 24:S21-S27.
10. Magee L.A. Pre-eclampsia and increased cardiovascular risk. Br Med J 2007, 335:945-946.
11. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J 2007, 335:974-977.
12. Magnussen E.B., Vatten L.J., Lund-Nilsen T.I., Salvesen K.A., Smith G.D., Romundstad P.R. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. Br Med J 2007, 335:978-981.
13. Paidas M.J., Ku D.H.W., Arkel Y.S. Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. Clin Perinatol 2004, 31. 783-+.
14. Lin J., August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005, 105:182-192.
15. He S., Bremme K., Blomback M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coagul Fibrinolysis 1997, 8:232-238.
16. DG M Hematologic evidence of disseminated intravascular coagulation in eclampsia. Obstet Gynecol Surv 1972, 399-417.
17. Howie P.W., Prentice C.R., McNicol G.P. Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency. J Obstet Gynaecol Br Commonw 1971, 78:992.
18. Redman C.W.G., Denson K.W.E., Beilin L.J., Bolton F.G., Stirrat G.M. Factor-VIII consumption in pre-eclampsia. Lancet 1977, 2:1249-1252.
19. Aznar J., Gilabert J., Estelles A., Espana F. Fibrinolytic-activity and protein-c in preeclampsia. Thromb Haemost 1986, 55:314-317.
20. Schjetlein R., Abdelnoor M., Haugen G., Husby H., Sandset P.M., Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Et Gynecol Scand 1999, 78:191-197.
21. Higgins J.R., Walshe J.J., Darling M.R.N., Norris L., Bonnar J. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 1998, 179:520-526.
22. Dusse L.M., Carvalho M.G., Getliffe K., Voegeli D., Lwaleed B.A., Cooper A.J. Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta 2008, 387:168-171.
23. VanWijk M.J., Boer K., Berckmans R.J., et al. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002, 88:415-420.
24. Weiner C.P. Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia. Lancet 1977, 1249-1252. J B (Ed.).
25. Dusse L.M., Carvalho M.G., Getliffe K., Voegeli D., Lwaleed B.A., Cooper A.I. Total plasma tissue factor pathway inhibitor levels in pre-eclampsia. Clin Chim Acta 2008, 388:230-232.
26. Redman C.W.G., Bonnar J., Beilin L. Early platelet consumption in pre-eclampsia. Br Med J 1978, 1:467-469.
27. Cadroy Y., Grandjean H., Pichon J., et al. Evaluation of 6 markers of hemostatic system in normal-pregnancy and pregnancy complicated by hypertension or preeclampsia. Br J Obstet Gynaecol 1993, 100:416-420.
28. Rakoczi I., Tallian F., Bagdany S., Gati I. Platelet life-span in normal-pregnancy and pre-eclampsia as determined by a non-radioisotope technique. Thromb Res 1979, 15:553-556.
29. Estelles A., Gilabert J., Grancha S., et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 1998, 79:500-508.
30. Mantovani A., Dejana E. Cytokines as communication signals between leukocytes and endothelial-cells. Immunol Today 1989, 10:370-375.
31. Vince G.S., Starkey P.M., Austgulen R., Kwiatkowski D., Redman C.W.G. Interleukin-6, tumor-necrosis-factor and soluble tumor-necrosis-factor receptors in women with preeclampsia. Br J Obstet Gynaecol 1995, 102:20-25.
32. Lim K.H., Rice G.E., Degroot C.J.M., Taylor R.N. Plasma type-II phospholipase A(2) levels are elevated in severe preeclampsia. Am J Obstet Gynecol 1995, 172:998-1002.
33. Takagi Y., Nikaido T., Toki T., et al. Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch 2004, 444:49-55.
34. Tsukimori K., Fukushima K., Tsushima A., Nakano H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. Hypertension 2005, 46:696-700.
35. Tsukimori K., Maeda H., Ishida K., Nagata H., Koyanagi T., Nakano H. The superoxide generation of neutrophils in normal and preeclamptic pregnancies. Obstet Gynecol 1993, 81:536-540.
36. Huppertz B., Frank H.G., Kingdom J.C.P., Reister F., Kaufmann P. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem Cell Biol 1998, 110:495-508.
37. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38:S26-S34.
38. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
39. Levi M., van der Poll T., Buller H.R. Bidirectional relation between inflammation and coagulation. Circulation 2004, 109:2698-2704.
40. Hou L., Howells G.L., Kapas S., Macey M.G. The protease-activated receptors and their cellular expression and function in blood-related cells. Br J Haematol 1998, 101:1-9.
41. Naldini A., Carney D.H., Bocci V., et al. Thrombin enhances T-cell proliferative responses and cytokine production. Cell Immunol 1993, 147:367-377.
42. Cunningham M.A., Romas P., Hutchinson P., Holdsworth S.R., Tipping P.G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999, 94:3413-3420.
43. Katusic Z.S., Vanhoutte P.M. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989, 257:H33-H37.
44. Gryglewski R.J., Palmer R.M.J., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456.
45. Cosentino F., Sill J.C., Katusic Z.S. Role of superoxide anions in the mediation of endothelium-dependent contractions. Hypertension 1994, 23:229-235.
46. Ernofsson M., Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996, 83:307-320.
47. Neumann F.J., Marx N., Gawaz M., et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997, 95:2387-2394.
48. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998, 9:S9-S14.
49. Bernardo A., Ball C., Nolasco L., Moake J.F., Dong J.F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004, 104:100-106.
50. Levi M., van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008, 34:459-468.
51. Esmon C.T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002, 561-564.
52. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001, 184:258-274.
53. Griffin J.H., Fernandez J.A., Gale A.J., Mosnier L.O. Activated protein C. J Thromb Haemost 2007, 5:73-80.
54. Esmon C.T. The endothelial cell protein C receptor. Thromb Haemost 2000, 83:639-643.
55. Mosnier L.O., Griffin J.H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003, 373:65-70.
56. Lao T.T., Yin J.A., Ng W.K., Yuen P.M.P. Relationship between maternal antithrombin-iii and protein-c protein-s levels before, during and after delivery. Gynecol Obstet Investig 1990, 30:87-90.
57. Krauss T., Augustin H.G., Osmers R., Meden H., Unterhalt M., Kuhn W. Activated protein C resistance and Factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998, 92:457-460.
58. Nesheim M. Thrombin fibrinolysis Chest 2003, 124:33S-39S.
59. Myles T., Nishimura T., Yun T.H., et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278:51059-51067.
60. Mao S.S., Cooper C.M., Wood T., Shafer J.A., Gardell S.J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B - modulation by glycosaminoglycans. J Biol Chem 1999, 274:35046-35052.
61. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430.
62. Biemond B.J., LM, Ten Cate H., Van der Poll T., Büller H.R., Hack C.E., Ten Cate J.W. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995, 587-594.
63. Vanderpoll T., Levi M., Hack C.E., et al. Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994, 179:1253-1259.
64. Han K.H., Hong K.H., Park J.H., et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004, 109:2566-2571.
65. Devaraj S., Xu D.Y., Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Circulation 2003, 107:398-404.
66. Szaba F.M., Smiley S.T. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002, 99:1053-1059.
67. Shrivastava S., McVey J.H., Dorling A. The interface between coagulation and immunity. Am J Transplant 2007, 7:499-506.
68. Wolf P. Nature and significance of platelet products in human plasma. Br J Haematol 1967, 13:269.
69. Meziani F., TA, Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol Rep 2008, 75-84.
70. Distler J.H.W., Huber L.C., Gay S., Distler O., Pisetsky D.S. Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 2006, 39:683-690.
71. Martin S., Tesse A., Hugel B., et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 2004, 109:1653-1659.
72. Tesse A., Martinez M.C., Hugel B., et al. Upregulation of proinflammatory proteins through NF-kappa B pathway by shed membrane microparticles results in vascular hyporeactivity. Arterioscler Thromb Vasc Biol 2005, 25:2522-2527.
73. Kim H.K., Song K.S., Chung J.H., Lee K.R., Lee S.N. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004, 124:376-384.
74. Gando S., Kameue T., Morimoto Y., Matsuda N., Hayakawa M., Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002, 30:1729-1734.
75. Barry O.P., Pratico D., Savani R.C., FitzGerald G.A. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Investig 1998, 102:136-144.
76. Martinez M.C., Tesse A., Zobairi F., Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 2005, 288:H1004-H1009.
77. Lok C.A.R., Van Der Post J.A.M., Sargent I.L., et al. Changes in microparticle numbers and cellular origin during pregnancy and preeclampsia. Hypertens Pregnancy 2008, 27:344-360.
78. Meziani F., Tesse A., David E., et al. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol 2006, 169:1473-1483.
79. VanWijk M.J., Nieuwland R., Boer K., van der Post J.A.M., VanBavel E., Sturk A. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction?. Am J Obstet Gynecol 2002, 187:450-456.
80. Lok C.A.R., Jebbink J., Nieuwland R., et al. Leukocyte activation and circulating leukocyte-derived microparticles in preeclampsia. Am J Reprod Immunol 2009, 61:346-359.
81. Toth B., Lok C.A.R., Boing A., et al. Microparticles and exosomes: impact on normal and complicated pregnancy. Am J Reprod Immunol 2007, 58:389-402.
82. Bretelle F., Sabatier F., Desprez D., et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003, 89:486-492.
83. Gonzalez-Quintero V.H., Jimenez J.J., Jy W., et al. Elevated plasma endothelial microparticles in preeclampsia. Am J Obstet Gynecol 2003, 189:589-593.
84. Gonzalez-Quintero V.H., Smarkusky L.P., Jimenez J.J., et al. Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. Am J Obstet Gynecol 2004, 191:1418-1424.
85. Germain S.J., Sacks G.P., Soorana S.R., Sargent I.L., Redman C.W. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007, 178:5949-5956.
86. Redman C.W.G., Sargent I.L. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 2008, 29:S73-S77.
87. Redman C.W.G., Sargent I.L. Microparticles and immunomodulation in pregnancy and pre-eclampsia. J Reprod Immunol 2007, 76:61-67.
88. Goswami D., Tannetta D.S., Magee L.A., et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2006, 27:56-61.
89. Guller S. Role of the syncytium in placenta-mediated complications of preeclampsia. Thromb Res 2009, 389-392.
90. Aly A.S., Khandelwal M., Zhao J., Mehmet A.H., Sammel M.D., Parry S. Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia. Am J Obstet Gynecol 2004, 190:252-258.
91. Gupta A.K., Rusterholz C., Huppertz B., et al. A comparative study of the effect of three different syncytiotrophoblast micro-particles preparations on endothelial cells. Placenta 2005, 26:59-66.
92. Aagaard-Tillery K.M., Belfort M.A. Eclampsia: morbidity, mortality, and management. Clin Obstet Gynecol 2005, 48:12-23.